Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
$62.64
$0.33(1.68%)
At close: 4:00 PM EST
$62.64
$0.33(1.68%)
Day’s Range― - ―
52-Week Range$9.57 - $76.76
Previous CloseN/A
Volume680.40K
Average Volume (3M)3.13M
Market Cap
$9.03B
Enterprise Value$9.32B
Total Cash (Recent Filing)$916.61M
Total Debt (Recent Filing)$312.77M
Price to Earnings (P/E)40.7
Beta2.50
Next Earnings
May 07, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding140,032,200
10 Day Avg. Volume4,445,280
30 Day Avg. Volume3,129,281
Financial Highlights & Ratios
PEG Ratio28.35
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit8.59
Enterprise Value/Ebitda25.18
Forecast
1Y Price Target
$82.00Price Target Upside30.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Uptake And ReimbursementEarly launch demonstrated broad prescription uptake across diverse prescribers and positive payer interactions with patient support programs that lowered out-of-pocket costs, indicating potential for steady commercial momentum.
Obesity Program EfficacyCombination data showing ARO-INHBE plus an incretin produced substantially greater weight loss and MRI-confirmed reductions in visceral and liver fat while preserving lean mass, suggesting a differentiated add-on therapy profile.
Regulatory ApprovalsApprovals secured in Canada and China with additional approvals expected in the United Kingdom and European Union would expand market access and support revenue upside.
Bears Say
Competitive UptakeA competing triglyceride therapy showing stronger-than-anticipated market uptake may limit commercial share and slow adoption of the company's product in target indications.
Financing And Cash BurnHigher-than-expected quarterly cash burn and a recent financing event increase the likelihood of future equity raises and potential shareholder dilution, pressuring near-term valuation.
Safety ConcernsBlinded trial reports of acute pancreatitis events present a meaningful safety risk that could complicate regulatory reviews and clinician willingness to prescribe.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $76.76 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $9.03B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 85 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Feb 05, 2026. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.037 by $0.183.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -1.04.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 140,032,200 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of $0.22 in its last earnings report, beating expectations of $0.037. Following the earnings report the stock price went down -0.186%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrowhead Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$82.00 (30.91% Upside)
$82.00 (30.91% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
209.48%
12-Months-Change
Fundamentals
Return on Equity
65.14%
Trailing 12-Months
Asset Growth
58.25%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
ARWR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive progress: first product approval and launch (REDEMPLO), robust efficacy data (PALISADE median TG reduction ~80%), significant non-dilutive and dilutive financing activity that strengthened the balance sheet ($1.33B of transactions and ~$917M reported cash), and encouraging early clinical signals across obesity and CNS programs (≈2x weight loss with ARO-INHBE combo; −88% ALK7 mRNA). Offsetting risks include limited early commercial data (only ~100 prescriptions in a 10‑week window), heavy reliance on collaboration/milestone revenue this quarter versus product sales, materially higher operating expenses (+$59M, ~36% YoY), and several programs still early/blinded with data uncertainties. On balance, the highlights—regulatory approvals, commercial launch execution, large financing and advancing pipeline with meaningful early clinical readouts—outweigh the lowlights, which are largely timing, early-stage uncertainty and expected near-term cost increases.View all ARWR earnings summariesARWR Stock 12 Month Forecast
Average Price Target
$82.00
▲(30.91% Upside)
Technical Analysis
Ownership Overview
3.81% Insiders
18.39% Mutual Funds
0.53% Other Institutional Investors
49.55% Public Companies and
Individual Investors